3CPLro-IN-2 is a potent, orally active SARS-CoV-2 3CLpro inhibitor with IC50 and Ki values of 1.55 and 6.09 μM, respectively; it targets the 3-chymotrypsin-like cysteine protease (3CLpro), an essential protein for viral replication and an attractive molecular target for combating COVID-19.